Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study

Yu, Dongni; Zou, Mingzhu; Pan, Qi; Yan, Shuicheng; Li, Miao; Zhang, Xianbo; Zhou, Yan; Wang, Xiaoxia; Guo, Lixin

doi:10.3389/fendo.2022.951570

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results came from Yu et al (120). They enrolled a population of patients with a BMI > 28 kg/m 2 with a prior diagnosis of DM II who had not undergone lifestyle interventions.…”

Section: Principal Side Effectssupporting

confidence: 68%

“…They were divided into a study group (receiving liraglutide) and a control group (undergoing lifestyle interventions). After 12 weeks of follow-up, the liraglutide group obtained a more significant reduction of VTA calculated by the energy spectrum CT (−7.1 ± 10.17 cm 2 in the study group vs. 0.91 ± 16.59 cm 2 in the control group) (120).…”

Section: Principal Side Effectsmentioning

confidence: 87%

See 1 more Smart Citation

Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options

Cesaro

Michele

Fimiani

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Obesity is a heterogeneous disease that affects almost one-third of the global population. A clear association has been established between obesity and cardiovascular disease (CVD). However, CVD risk is known to be related more to the local distribution of fat than to total body fat. Visceral adipose tissue (VAT) in particular has a high impact on CVD risk. This manuscript reviews the role of VAT in residual CV risk and the available therapeutic strategies for decreasing residual CV risk related to VAT accumulation. Among the many pathways involved in residual CV risk, obesity and particularly VAT accumulation play a major role by generating low-grade systemic inflammation, which in turn has a high prognostic impact on all-cause mortality and myocardial infarction. In recent years, many therapeutic approaches have been developed to reduce body weight. Orlistat was shown to reduce both weight and VAT but has low tolerability and many drug-drug interactions. Naltrexone-bupropion combination lowers body weight but has frequent side effects and is contraindicated in patients with uncontrolled hypertension. Liraglutide and semaglutide, glucagon-like peptide 1 (GLP-1) agonists, are the latest drugs approved for the treatment of obesity, and both have been shown to induce significant body weight loss. Liraglutide, semaglutide and other GLP-1 agonists also showed a positive effect on CV outcomes in diabetic patients. In addition, liraglutide showed to specifically reduce VAT and inflammatory biomarkers in obese patients without diabetes. GLP-1 agonists are promising compounds to limit inflammation in human visceral adipocytes.

show abstract

“…Similar results came from Yu et al (120). They enrolled a population of patients with a BMI > 28 kg/m 2 with a prior diagnosis of DM II who had not undergone lifestyle interventions.…”

Section: Principal Side Effectssupporting

confidence: 68%

Section: Principal Side Effectsmentioning

confidence: 87%

Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options

Cesaro

Michele

Fimiani

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…[ 9 , 10 ] GLP-1 receptors are distributed in the gastrointestinal tract, cardiomyocytes, endothelial cells, and sinus node. [ 11 , 12 ] Therefore, liraglutide may exert cardioprotective effects by modulating cardiac function and preserving cardiomyocytes. Studies have demonstrated the efficacy of liraglutide in preventing and treating vascular complications of diabetes and alleviate myocardial damage.…”

Section: Introductionmentioning

confidence: 99%

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

Xia,

Yu,

Lei

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Liraglutide widely utilized in type 2 diabetes treatment, has elicited conflicting findings regarding its impact on cardiac function in patients with this condition. Therefore, The objective of this study was to conduct a meta-analysis of randomized controlled trials (RCTs) to evaluate the effects of liraglutide on cardiac function in patients diagnosed with type 2 diabetes. Methods: We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes. Data were synthesized with the fixed-effect models to generate standard mean differences (SMDs) with 95% confidence intervals (CIs) of each outcome for liraglutide versus placebo. The risk of bias would be assessed according to the Cochrane Risk of Bias Tool, while meta-analysis would be conducted using Revman 5.3.0 software. The evidence was graded based on the Grading of Recommendations Assessment, Development and Evaluation approach. Results: The meta-analysis encompassed 5 RCTs including 220 participants. Results revealed that liraglutide exhibited significant enhancements in left ventricular ejection fraction [SMD = −0.38, 95%CI(−0.70, −0.06), P = .02], cardiac index [SMD = −1.05, 95%CI(−1.52, −0.59), P < .0001], stroke volume [SMD = −0.67, 95%CI(−1.02, −0.32), P = .0002] and early diastolic filling velocity/late atrial filling velocity ratio [SMD = −0.52, 95%CI(−0.82, −0.22), P = .0006]. However, no statistically significant impact on cardiac output [SMD = −0.20, 95%CI(−0.53, 0.14), P = .26], early diastolic filling velocity/early diastolic annular velocity (E/Ea) ratio [SMD = −0.34, 95%CI(−0.75, 0.06), P = .10] and early diastolic filling velocity/early diastolic mitral annular velocity ratio [SMD = 0.21, 95%CI(−0.15, 0.56), P = .25] was observed. The Grading of Recommendations Assessment, Development and Evaluation evidence quality ratings indicated that all the outcome measures included in this study were evaluated as having low and very low quality. Conclusion: The available evidence suggested that liraglutide may exert a favorable impact on cardiac function in patients with type 2 diabetes. Consequently, the utilization of liraglutide as a preventive measure against heart failure incidents in individuals with type 2 diabetes represents a promising strategy. However, robust evidence support requires the conduct of large-scale, multicenter high-quality RCTs.

show abstract

The effect of obesity pharmacotherapy on body composition, including muscle mass

Argyrakopoulou,

Gitsi,

Konstantinidou

et al. 2024

Int J Obes

View full text Add to dashboard Cite

Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study

Cited by 5 publications

References 27 publications

Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options

Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

The effect of obesity pharmacotherapy on body composition, including muscle mass

Contact Info

Product

Resources

About